LIDDS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1595 SEK | +2.90% |
|
-6.18% | +47.69% |
| 21/03 | Sweden's Lidds Finalizes Purchase of Noviga Research | MT |
| 21/03 | LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB. | CI |
| Sales 2021 | 3.55M 325K 27.09M | Sales 2022 | 1.89M 173K 14.39M | Capitalization | 58.92M 5.39M 449M |
|---|---|---|---|---|---|
| Net income 2021 | -37M -3.38M -282M | Net income 2022 | -36M -3.29M -274M | EV / Sales 2021 | 81.8 x |
| Net cash position 2021 | 34M 3.11M 259M | Net cash position 2022 | 1.26M 116K 9.63M | EV / Sales 2022 | 30.5 x |
| P/E ratio 2021 |
-8.2
x | P/E ratio 2022 |
-1.58
x | Employees | 2 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 63.36% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.90% | ||
| 1 week | -6.18% | ||
| Current month | -19.44% | ||
| 1 month | -19.44% | ||
| 3 months | -41.79% | ||
| Current year | +47.69% |
1 week
0.15
0.17
1 month
0.140.20
Current year
0.110.46
1 year
0.101.38
3 years
0.1017.00
5 years
0.1022.00
10 years
0.1023.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/21/01 | |
Kia Bengtsson
PRN | Corporate Officer/Principal | - | 01/22/01 |
Niklas Axén
PRN | Corporate Officer/Principal | 61 | 01/04/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 62 | 09/01 | |
| Director/Board Member | 62 | 09/01 | |
David Bejker
BRD | Director/Board Member | 49 | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.1595 | +2.90% | 57,711 |
| 25/24/25 | 0.155 | -4.91% | 56,183 |
| 24/24/24 | 0.163 | -0.31% | 10,798 |
| 23/24/23 | 0.1635 | +2.19% | 135,173 |
| 22/24/22 | 0.16 | -5.88% | 78,950 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:18 pm IST
More quotes
Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Companyâs portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.
Calendar
15/05/2024
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +47.69% | 993K | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LIDDS Stock
